Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) serves as a notification to the U.S. Securities and Exchange Commission regarding the submission of its Annual Report on Form 20-F. The filing, dated March 15, 2021, covers the audited financial statements for the fiscal year ended December 31, 2020.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts solely as a notice of the availability of the full Annual Report containing these metrics.
Material Changes
No material changes or comparative financial data are disclosed within this specific filing text. Investors are directed to the full Form 20-F for detailed year-over-year analysis.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to various risks and uncertainties. These factors are detailed under Item 3.D "Risk factors" in the 2020 Annual Report on Form 20-F. No specific guidance or management commentary on future performance is included in this text.
Important Facts for Investors to Verify
- The full audited financial statements for the year ended December 31, 2020, are available online at www.gsk.com/corporatereporting and www.sec.gov.
- Hard copies of the 2020 Annual Report and the Notice of Annual General Meeting were expected to be available on or about March 30, 2021.
- Shareholders may request free hard copies of the audited financial statements via Equiniti Limited (UK), J.P. Morgan Chase Bank, N.A. (US), or the GSK Response Center (USA).
- Investors should review the "Risk factors" section in the Form 20-F to understand uncertainties affecting forward-looking statements.